Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Results of disease-oriented phase II trials with cis-dichlorodiammineplatinum(II) (cis-platinum) in 135 adequately treated patients with advanced urothelial tumors at Memorial Sloan-Kettering Cancer Center are presented. In four protocols which used cis-platinum alone or in combination with Adriamycin and/or cyclophosphamide in 95 patients with bladder cancer, no significant difference (46%--54%) in the number of partial remissions (PRs) in previously untreated patients was noted. The median duration of response in three of the four protocols was 5--7 months. A review of the literature indicates that cis-platinum used singly produced remissions in 45% of 67 patients (95% confidence limit, 12%--57%). In the treatment of superficial bladder tumors, intravesically administered cis-platinum induced few complete or sustained remissions. The difficulties in evaluating response with intravesical therapy are discussed. The importance of patient selection, particularly the need to include patients with objectively measurable disease parameters, in phase II trials is stressed. Differences in patient characteristics and response criteria will necessitate prospective randomized trials of cis-platinum alone versus cis-platinum combination regimens in the treatment of metastatic disease. cis-Platinum was inactive (12% PRs) in 25 patients with prostatic cancer who had objectively measurable parameters. It is of interest that PRs were obtained in three of six patients (50%) with penile cancer. A review of the literature and the data in the present series indicates that cis-platinum has no value in the treatment of metastatic hypernephroma.
 ...
PMID:Phase II trials with cis-dichlorodiammineplatinum(II) in the treatment of urothelial cancer. 38 26

The aim of the present study is to analyse the response in patients with cancer of the urogenital region to a primary antigen 2-4 dinitrochlorobenzene (DNCB). A total of 69 patients with neoplastic disease were studied (13 cases with kidney cancer, 34 cases with bladder cancer, 13 cases with prostatic cancer, 5 cases with testicular cancer, one case with penis cancer, and 3 cases with cancer of the cervix, comparatively with 13 patients with non-malignant urological diseases. Whereas in the control group, 78% of the patients gave a positive skin reaction to DNCB, 15% of the patients with kidney cancer, 56% of the patients with bladder cancer, 69% of the patients with prostatic cancer and 60% of the patients with testicular cancer gave a positive reaction. If we consider the stages of the disease, the reaction was positive, in 91% of bladder cancer at stage I and in 47% at stages II and III in 100% of prostatic cancer at stage I and in 62% at stages II and III, in 60% of testicular cancer at stage IV (but 100% of seminomas and 0% of dysembryomas have a positive reaction). It would therefore seem that a correlation exists between the degree of the extension of the disease and the skin reaction to DNCB.
 ...
PMID:Cutaneous response to dinitrochlorobenzene in patients with genito-urinary cancers. 85 14

Urological tumors were examined for the presence of human papillomavirus (HPV) DNA by using Southern blot hybridization. In 20 male patients with condyloma acuminatum, HPV type 6 was found at 85% (17/20), HPV type 11 at 95% (19/20), HPV type 16 at 5% (1/20) and HPV type 18 at 0% (0/20). In 2 female patients with condyloma acuminatum, HPV types 6, 11, 16 and 18 were found at 100% (2/2), 100% (2/2), 50% (1/2) and 0% (0/2), respectively. All 6 of the patients who were positive for HPV type 6, were also positive for HPV type 11. Two patients were positive for HPV types 6, 11 and 16, the last of which was frequently found in penile cancer and uterine cervical cancer. In 6 patients with penile cancer, two patients were positive for HPV type 16 and negative for HPV types 6, 11 and 18. The remaining 4 patients were negative for all these HPV types. One patient who was positive for HPV type 16 had penile cancer after three previous episodes of penile condyloma acuminatum. From this information, a malignant change in the condyloma acuminatum was assumed to indicate the possible association of HPV type 16 with the process of malignant degeneration. HPV types, 6, 11, 16 and 18 were not detected in a female patient with vulvar cancer. Although HPV was thought to participate in the development of urological tumors except for external genital tumors, all patients examined, consisting of 2 with benign prostatic hypertrophy, 5 with prostatic cancer and 24 with bladder cancer, were negative for HPV types 6, 11, 16 and 18. Eight patients with bladder cancer were negative for HPV type 33.
 ...
PMID:[Studies of human papillomavirus (HPV) in urological tumors]. 196 28

Testicular cancer is divided pathologically into two categories; seminoma and non-seminomatous germ cell tumor (NSGCT). Seminoma is a radio-sensitive tumor, so that radiation has been mainly used for stages I and II. Stage III seminoma is treated in the same way as NSGCT. Several years ago stages I and II NSGCT were treated primarily by retroperitoneal lymph node dissection. These days, chemotherapy, such as PVB, or VAB-6 therapy, is adopted as the first choice of treatment, followed by surgical intervention to elucidate the remaining bulky mass if present. Stage III NSGCT is also managed by chemotherapy. By these procedures 70-90% CR of patients with NSGCT is obtained. Prostatic cancer has been treated mainly according to its stages. As for stage A cancer palliative therapy has been shown to yield good results. However, in the case of poorly-differentiated tumors, local irradiation with anti-androgenic treatment should be employed. Stage B cancer should be treated by radical surgery. Local lymph node dissection is usually indicated. In addition local irradiation and anti-androgenic therapy should be considered. Most stage C or D patients do well for a while with antiandrogenic therapy. Within two or three years, however, drug resistance ensues, recessitating a change in the therapeutic modality. Treatments of choice include in chemotherapy, radiotherapy, and others. Treatment of penile cancer involves chemotherapy with bleomycin and irradiation, which result in considerable improvement.
 ...
PMID:[Selection of treatment from a pathophysiological point of view. II: Studies on male urogenital tumors]. 241 89

Magnetic resonance imaging (MRI) was performed on 49 urological tumors (11 renal cell carcinomas, 3 renal pelvic cancers, 2 renal angiomyolipomas, 1 renal leiomyosarcoma, 1 large renal cyst, 4 adrenal tumors, 11 bladder cancers, 2 bone metastasis from bladder cancer, 10 prostatic cancers, 1 prostatic sarcoma, 1 urethral cancer, 1 penile cancer and 1 perivesical granuloma) since October 1985 to September 1986. MRI was performed using a Signa (G.E.) with a 1.5T superconductive magnet and 3 images, including T1 weighted image, T2 weighted image, and proton density image, were obtained. In conclusion MRI is a noninvasive examination and gives more information than computed tomography despite its high cost. In renal cell carcinoma, the chemical shift in MRI and clear visualization of tumor thrombus enable accurate staging. Differential diagnosis from other renal mass lesions may be possible by the T2 weighted image. In adrenal disease, most of the adrenal masses can be differentiated, but in some cases it is impossible. In bladder cancer, wall invasion of tumor may be evaluated in T2 weighted image, and MRI is suitable for staging of locally advanced tumor. In prostatic cancer, visualization of periprostatic plexus and differentiation between internal and external gland may enable local staging and identification of low stage tumors.
 ...
PMID:[Differential diagnosis and staging of urological tumors by magnetic resonance imaging compared with computed tomography]. 359 84

A case of a 79-year-old man with penile cancer and prostate cancer is reported. The pathological study of surgical specimens disclosed well-differentiated squamous cell carcinoma of the penis and poorly differentiated adenocarcinoma of the prostate. This is a rare case of multiple primary malignant neoplasms associated with penile cancer and prostate cancer.
 ...
PMID:[A case of primary malignant neoplasms associated with penile cancer and prostatic cancer]. 381 49

In an international collaboration project we combined cancers of the male genital tract among Inuit identified from routine cancer registry systems in the Circumpolar region (Alaska, Canada and Greenland) and compared incidence rates with rates in Denmark, Connecticut (USA) and Canadian non-Inuit. We observed a low risk of prostate cancer (standardized incidence ratio (SIR) 0.2-0.3) and the incidence rate of 7.8 per 100 000 (world standard) is among the lowest in the world. Dietary and not diagnostic factors are likely explanations of this finding. Testicular cancer also occurred with low rates (SIR 0.3-0.7) although only significantly so when compared with Denmark and Connecticut (USA) which have some of the world's highest incidence rates of this cancer. Penile cancer occurred with relatively high risk (SIR 1.8-3.0) based on rates among non-Inuit. The incidence is, however, lower than anticipated considering the possibility for shared risk factors with cancer of the uterine cervix.
 ...
PMID:Cancer of the male genital tract in Circumpolar Inuit. 881 66

For different reasons cancers of the Prostate, Testis and Penis are important diseases for men. The incidence for prostate and testicular cancers are more commonly seen in developed countries, while penile cancer occurs more frequently in the developing countries. In Mumbai the incidence of prostatic and testicular cancers is low whereas penile cancer is high when compared with international reports. In Mumbai. The incidence of prostatic cancer increases only after the age of 50. The age specific incidence rates for testicular cancers are bimodal whereas the incidence of Penile cancer increases exponentially with age, after the age 30. In Mumbai. The incidence of Prostate cancer was six times higher in the Parsis as compared to other communities. The incidence of cancer of the testis is lowest in Hindus and cancer of penis is not seen in Muslims. The incidence of prostate cancer was highest among Gujrathis and there was an absence of penile cancer in Urdu speaking men. In Bombay the incidence of cancers of the prostate, testis and penis seem to be associated with marital status. The association between incidence and education level of the patients was only found in men having cancer of the testis. There seems to be an increase in age adjusted incidence rates for cancers of the prostate and testis over time period of 30 years, whereas penile cancer incidence was decreasing over the same period.
 ...
PMID:Descriptive epidemiology of the cancers of male genital organs in greater Bombay. 949 61

Human papillomavirus is thought to be an etiological factor for urological tumors such as penile cancer. However, there is much conflicting data surrounding prostatic cancer. We recently established a highly sensitive nested PCR method with consensus human papillomavirus (HPV) primers for the detection of many high-risk HPV types. HPV DNA from the long-control region (LCR) to E7 open reading frame was amplified with first primer pairs and subsequently amplified with second internal E6-E7 primers. Our nested PCR method could detect HPV16, 18, 31, 33, 35, 52, 58 and some undetermined HPV DNAs. Using this method, we investigated the existence of HPV DNA in formalin-fixed paraffin-embedded tissue of the prostate. We found HPV DNA in three of 71 specimens of benign prostatic hyperplasia (BPH) and in none of 38 prostatic carcinomas. These three samples were infected with HPV 16. These results suggest that HPV is not a causal factor for prostatic cancer and BPH.
 ...
PMID:Detection of human papillomavirus (HPV) DNA in archival specimens of benign prostatic hyperplasia and prostatic cancer using a highly sensitive nested PCR method. 969 97

We studied social class variation in the incidence of cancers of the prostate, testis, penis and scrotum among 1.1 million Finnish men (45-69 years of age) during 1971-95. The incidence of prostate cancer (6,972 cases) was increasing during the study period; the highest at all the times occurred in Social Class I (highest social class), 40-50% higher than in Social Class IV (lowest). The social class gradient was strongest in localized disease but there was some variation in incidence of non-localized prostate cancer. A total of 174 testicular cancer cases were diagnosed during the study period. In the early 1970s, the incidence of testicular cancer in Social Class I was 5-fold compared to Social Classes III and IV. Thereafter, the incidence rate decreased in Social Class I, but increased in the lower classes. The positive social class gradient was similar for seminomas and non-seminomas. For penile cancer (n = 128), the incidence decreased over time and social class variation was small. Only 6 cases of scrotum cancer were observed. In testicular cancer the strong positive social class association in the early 1970s is disappearing along with converging incidence trend slopes in different social classes. The difference diminished to less than 2-fold in the 1990s. Reasons for this observation remain open.
 ...
PMID:Socio-economic differences in incidence rates of cancers of the male genital organs in Finland, 1971-95. 1244 8


1 2 3 4 5 Next >>